MVA-BN
Phase 2Active 0 watching 0 views this week⚡ Active
49
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Monkeypox (Mpox)
Conditions
Monkeypox (Mpox)
Trial Timeline
Oct 21, 2024 → May 7, 2026
NCT ID
NCT06549530About MVA-BN
MVA-BN is a phase 2 stage product being developed by Bavarian Nordic for Monkeypox (Mpox). The current trial status is active. This product is registered under clinical trial identifier NCT06549530. Target conditions include Monkeypox (Mpox).
Hype Score Breakdown
Clinical
17
Activity
12
Company
7
Novelty
5
Community
5
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06549530 | Phase 2 | Active |
| NCT00189943 | Phase 1 | Completed |
Competing Products
5 competing products in Monkeypox (Mpox)
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| BNT166a | BioNTech | Phase 1/2 | 38 |
| BNT166a | BioNTech | Phase 2 | 49 |
| MVA-BN standard regimen + MVA-BN half-dose regimen | Bavarian Nordic | Phase 3 | 74 |
| JYNNEOS (Liquid Formulation) + JYNNEOS (Lyophilized Formulation) | Bavarian Nordic | Phase 3 | 74 |
| Jynneos + MVA-BN (Quail) | Bavarian Nordic | Phase 2 | 49 |